廠商合計合併營收之變化:2020年5~7月國內上市櫃DRAM製造業者合併營收月增率呈現連續三個月負數態勢，反映先前DRAM下游客戶提前拉貨、DRAM供給釋出的轉疲狀況，換句話說，2020年以來下游客戶對於DRAM的拉貨動能已逐步告一段落，加上疫情所形成的遠端上班、線上教學等對於資料中心、伺服器、NB的需求略顯減緩，況且先前DRAM業者將產能移至CIS的部分又移回，因而使得2020年第二季~第三季DRAM價格走勢已明顯未如原先預期。

A skin barrier film is designed to manage fecal inconsistence in bedridden patients, and has proven to be effective even in prevention & infection control. It provides safer patient outcomes and augment ease of nursing. The devices help in attachment of ostomy bags to the individual’s body to maintain incontinence. The scope of the market includes revenue generated by different shapes of skin barrier devices and various surgeries carried with the help of these devices. However, revenue generated from diagnosis of disease and doctor's consultation fees are excluded from the report.

The market studied is largely driven by the increasing demand in topical analgesics, growth in the geriatric population resulting in the rising prevalence of various diseases, and the cost-efficiency of OTC analgesics drugs. The aged population is more likely to have arthritis, bone and joint disorders, cancer, and other chronic disorders associated with pain. Between 25% and 50% of community-dwelling elderly have several chronic problems. In recent years, the application of OTC analgesics has increased by leaps and bounds, providing great opportunities for improving the management of chronic pain, by improving the efficiency and efficacy of treatment. As per National Institute of Health (NIH), more than 30% of Americans are suffering from chronic pain. Additionally, data from CDC revealed that around 20.4% (50.0 million) of the US adults had chronic pain and 8.0% (19.6 million) had highimpact chronic pain, in 2016. This high prevalence rate denotes the importance of pain management drugs for treating chronic pain.

The report provides market dynamics and trends related to the global neurostimulation devices market. In addition, it presents the market estimations and forecast. The study estimates the revenue generated from the sales of neurostimulation devices directly from a company and does not include revenue related to neurostimulation services such as doctor fees, consulting, and rehabilitation services. The valuations comprise revenue generated from devices, which are used during neurostimulation therapies. However, the report does not include revenue generated by dealers, traders, or brokers of the market during the supply of these devices in hospitals, clinics, and surgery centers. Furthermore, it excludes revenue generated from post-sale services of devices.